Lymphoma: all 5,623 studies

Page 10 of 57. Open to participants first (823), then studies with results posted, then the rest; newest registration first within each.

• Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)Active, not recruitingNCT04439188Phase 2Results posted
• Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)Active, not recruitingNCT04439175Phase 2Results posted
• Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)Active, not recruitingNCT04439149Phase 2Results posted
• Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)Active, not recruitingNCT04439136Phase 2Results posted
• Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)Active, not recruitingNCT04439123Phase 2Results posted
• Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)Active, not recruitingNCT04439110Phase 2Results posted
• Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT04436107Phase 1Results posted
• Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)CompletedNCT04434937Phase 2Results posted
• Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell LymphomaCompletedNCT04432506Phase 2Results posted
• APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)TerminatedNCT04419389Phase 1/2Results posted
• Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell LymphomaCompletedNCT04402138Phase 2Results posted
• A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell LymphomaTerminatedNCT04362007Phase 1/2Results posted
• First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin LymphomasTerminatedNCT04358458Phase 1/2Results posted
• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04320888Phase 2Results posted
• 18F-FDG PET Radiomics of Diffuse Large B-cell LymphomaCompletedNCT04317313Results posted
• A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)CompletedNCT04317066Phase 1Results posted
• Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell LymphomaTerminatedNCT04314843Phase 1Results posted
• A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell LymphomaCompletedNCT04313608Phase 1Results posted
• Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With AlemtuzumabCompletedNCT04312841Phase 2Results posted
• Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFHTerminatedNCT04251065Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).TerminatedNCT04236141Phase 3Results posted
• Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"CompletedNCT04213209Results posted
• Acalabrutinib in Combination With R-ICE For Relapsed or Refractory LymphomaTerminatedNCT04189952Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT04182204Phase 3Results posted
• Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult ParticipantsTerminatedNCT04167137Phase 1Results posted
• T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin LymphomaTerminatedNCT04160195Phase 1Results posted
• Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT04155840Phase 2Results posted
• Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101TerminatedNCT04144140Phase 1Results posted
• Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCLCompletedNCT04134936Phase 1Results posted
• Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)CompletedNCT04105010Phase 1/2Results posted
• Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis FungoidesCompletedNCT04101331Phase 2Results posted
• A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin LymphomaTerminatedNCT04074330Phase 1/2Results posted
• Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT04052997Phase 2Results posted
• Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT04047797Phase 2Results posted
• A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin LymphomaCompletedNCT04038359Phase 2Results posted
• A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)TerminatedNCT04035434Phase 1/2Results posted
• Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)CompletedNCT04034056Results posted
• Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLLCompletedNCT04030195Phase 1/2Results posted
• Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell LymphomaCompletedNCT04002401Phase 2Results posted
• A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT03992339Phase 2Results posted
• Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)TerminatedNCT03990961Phase 2Results posted
• CMP-001 for Relapsed and Refractory LymphomaTerminatedNCT03983668Phase 1/2Results posted
• Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular LymphomaCompletedNCT03976102Phase 3Results posted
• HeartPhone Cancer Survivors Trial 2019TerminatedNCT03953326Phase 1/2Results posted
• A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell LymphomaTerminatedNCT03947255Phase 2Results posted
• Split-Dose R-CHOP for Older Adults With DLBCLActive, not recruitingNCT03943901Phase 2Results posted
• Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone LymphomaTerminatedNCT03919175Phase 2Results posted
• Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell MalignanciesCompletedNCT03905135Phase 1Results posted
• SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or LymphomasCompletedNCT03894618Phase 1Results posted
• Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular LymphomaTerminatedNCT03890289Phase 2Results posted
• TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced CancersCompletedNCT03884556Phase 1Results posted
• A Study of Copanlisib and Ibrutinib in Mantle Cell LymphomaCompletedNCT03877055Phase 1/2Results posted
• PROactive Evaluation of Function to Avoid CardioToxicityTerminatedNCT03862131Phase 2Results posted
• Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell TransplantationTerminatedNCT03856216Phase 2Results posted
• Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone LymphomaCompletedNCT03846427Phase 2Results posted
• Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaTerminatedNCT03828448Phase 2Results posted
• An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular LymphomaCompletedNCT03817853Phase 4Results posted
• PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaActive, not recruitingNCT03817320Phase 1/2Results posted
• Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FLCompletedNCT03806179Phase 1Results posted
• Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)CompletedNCT03792256Phase 1Results posted
• Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaCompletedNCT03788291Phase 2Results posted
• Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With LymphomasTerminatedNCT03786926Phase 1Results posted
• An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With LymphomaTerminatedNCT03779113Phase 1Results posted
• Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaTerminatedNCT03776864Phase 2Results posted
• Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell LymphomaCompletedNCT03770000Phase 1/2Results posted
• A Study of Isatuximab-based Therapy in Participants With LymphomaTerminatedNCT03769181Phase 1/2Results posted
• Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)TerminatedNCT03768505Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell LymphomaCompletedNCT03761056Phase 2Results posted
• A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)CompletedNCT03744676Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)TerminatedNCT03743246Phase 1/2Results posted
• Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell LymphomaCompletedNCT03742258Phase 1Results posted
• Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell TransplantationCompletedNCT03734601Phase 2Results posted
• A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic LeukemiaCompletedNCT03734016Phase 3Results posted
• Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"CompletedNCT03729609Results posted
• SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis FungoidesTerminatedNCT03713320Phase 2Results posted
• Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)CompletedNCT03711578Phase 2Results posted
• Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell LymphomaTerminatedNCT03704298Phase 1Results posted
• Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell LymphomaCompletedNCT03703375Phase 3Results posted
• Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell LymphomaActive, not recruitingNCT03696784Phase 1Results posted
• Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular LymphomaTerminatedNCT03685344Phase 1Results posted
• Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell LymphomaTerminatedNCT03684694Phase 1/2Results posted
• A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin LymphomaCompletedNCT03677141Phase 1/2Results posted
• Mobile Health Case Management System for Reducing Pediatric Treatment AbandonmentCompletedNCT03677128Not applicableResults posted
• Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With PembrolizumabCompletedNCT03674567Phase 1/2Results posted
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)TerminatedNCT03645395Phase 2Results posted
• Rituximab + Immunotherapy in Follicular LymphomaTerminatedNCT03636503Phase 1Results posted
• Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaTerminatedNCT03624036Phase 1Results posted
• Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched DonorsTerminatedNCT03615105Phase 2Results posted
• Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma PatientsCompletedNCT03610724Phase 2Results posted
• A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)CompletedNCT03595657Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT03589469Phase 2Results posted
• Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell LymphomasCompletedNCT03586999Phase 1/2Results posted
• Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT03583424Phase 1/2Results posted
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular LymphomaTerminatedNCT03571828Phase 1Results posted
• CC486-CHOP in Patients With Previously Untreated Peripheral T-cell LymphomaCompletedNCT03542266Phase 2Results posted
• Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell LymphomaCompletedNCT03534180Phase 2Results posted
• BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)CompletedNCT03520920Phase 2Results posted
• Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERSTerminatedNCT03495713Phase 2Results posted
• A Study Of The Selective PKC-β Inhibitor MS- 553TerminatedNCT03492125Phase 1/2Results posted
• Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or LymphomasCompletedNCT03489369Phase 1Results posted

← Lymphoma overview